^
    Back
    Association details:
    Biomarker:HER-2 positive + TP53 mutation
    Cancer:Biliary Tract Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB)

    Published date:
    11/09/2023
    Excerpt:
    This study was an investigator-initiated, open-label, single-arm, multi-institutional, phase II trial in adult patients with HER2-positive...The presence of isolated TP53 mutations was associated with inferior PFS compared with other mutations (TERT promoter, HER2, PIK3CA, etc) or no detected mutations (6.51 v 12.02 v 10.58 months; P < .001).
    Secondary therapy:
    cisplatin + gemcitabine
    DOI:
    https://doi.org/10.1200/JCO.23.01193